EFFECT OF MEGESTROL ACETATE AND TESTOSTERONE ON BODY COMPOSITION AND HORMONAL

醋酸甲地孕酮和睾酮对身体成分和荷尔蒙的影响

• 批准号: 8174495
• 负责人: RICHARD CASABURI
• 金额: $ 3.96万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8174495
• 关键词: Blood; Body Composition; Body Weight decreased; Chronic Obstructive Airway Disease; Computer Retrieval of Information on Scientific Projects Database; Control Groups; Dose; Exercise Tolerance; Funding; Grant; Hormonal; Inflammation Mediators; Institution; Intramuscular Injections; Megestrol Acetate; Normal Range; Oral cavity; Participant; Patients; Pilot Projects; Placebo Control; Research; Research Personnel; Resources; Source; Testosterone; United States National Institutes of Health; Weight Gain; Woman; men; muscle form; muscle strength

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will determine whether 12 weeks of taking both 800mg of megestrol acetate daily by mouth combined with testosterone given weekly by intramuscular injection increases body weight and muscle mass in COPD patients with involuntary weight loss. It will also determine whether there are increased exercise tolerance and muscle strength, changes in blood inflammatory mediators or changes in the level of everyday activity. Testosterone doses will be higher for men than for women and doses will be adjusted to achieve desired blood levels: for men, at the high end of the normal range for young men; for women, somewhat above the high end of the normal range for young women. This study is intended as a pilot study for a larger placebo-controlled, multi-center trial. There will be no control group; each patient will serve as their own control. We propose to treat 12 participants.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究将确定每日口服800 mg醋酸甲地孕酮联合每周肌肉注射睾酮12周是否会增加伴有不自主体重减轻的COPD患者的体重和肌肉质量。 它还将确定是否有运动耐量和肌肉力量增加，血液炎症介质的变化或日常活动水平的变化。 男性的睾酮剂量将高于女性，并且剂量将进行调整以达到所需的血液水平：对于男性，处于年轻男性正常范围的高端;对于女性，略高于年轻女性正常范围的高端。 本研究旨在作为一项大型安慰剂对照、多中心试验的初探性研究。 不设对照组;每位患者将作为自己的对照。 我们建议治疗12名参与者。